Skip to main content
. 2023 Apr 29;12(5):1033. doi: 10.3390/antiox12051033

Figure 2.

Figure 2

Dose-dependent effect of compounds 3aa and 3bc on microglial BV2 cells: (A) Viability assessment (mean ± SD) of BV2 cells in presence of LPS and variable doses of compounds 3aa and 3bc; (B) Dose-dependent inhibition (mean ± SD) of LPS-induced BV2 cell production of PGE2 variable doses of compounds 3aa and 3bc. Results were analyzed by ANOVA. * p < 0.05 versus LPS-treated control group.